October 16

2 comments

2016 WMIF | Epigenetics and Novel Cancer Targets

By heheals

October 16, 2020




Moderator: Pat Fortune, PhD, Senior Market Sector Leader, Partners Innovation
Robert Copeland, PhD, President of Research and Chief Scientific Officer, Epizyme
Keith Dionne, PhD, CEO, Constellation Pharmaceuticals, Inc.
Cigall Kadoch, PhD, Assistant Professor, DFCI, Harvard Medical School
Jeannie Lee, MD, PhD, Professor of Genetics, MGH
Nancy Simonian, MD, CEO, Syros Pharmaceuticals
Johnathan Whetstine, PhD, Tepper Family MGH Research Scholar, Associate Professor of Medicine, Harvard Medical School

The initiation and progression of cancer is controlled by both genetic and epigenetic events. Epigenetics, the study of changes that influence how DNA does its job, is one of the fastest-moving fields in cancer research. Expert corporate and academic panel members will discuss the promise of epigenetics. They will describe translating basic epigenetic research into cancer diagnostics and therapies, emphasizing market opportunities and competitive advantages.

source

heheals

About the author

Leave a Repl​​​​​y

Your email address will not be published. Required fields are marked

{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}

Never miss a good story!

 Subscribe to our newsletter to keep up with the latest trends!